People coinfected with HIV and HBV receiving combined treatment

Export Indicator

Proportion of people coinfected with HIV and HBV receiving combined treatment
What it measures

Proportion of people coinfected with HBV and HIV enrolled in HIV care being treated with antiretroviral medicines that are effective against both viruses


People living with HIV are often coinfected with HBV. The prevalence of coinfection is especially high in the WHO African Region and European Region because of early childhood transmission and injecting drug use, respectively. Treating hepatitis B among people living with HIV influences quality of life, life expectancy and mortality. Some antiretroviral medicines are effective against both HIV and HBV, which simplifies the treatment of coinfected people.


Number of people coinfected with HIV and HBV who receive treatment with antiretroviral medicines effective against both HIV and HBV during the reporting period


Number of people diagnosed with HIV and HBV coinfection in HIV care during a reporting period (12 months)



Method of measurement

The numerator and denominator are calculated from the clinical records of health-care facilities providing HIV treatment and care.

Measurement frequency



People who inject drugs

Additional information requested

This indicator corresponds to indicator C.7a of the viral hepatitis monitoring and evaluation framework, disaggregated by HIV status.

If this indicator is produced only in a subset of facilities, comment on the source of information, sample size and whether the information is representative of all sites where HIV treatment and care are delivered.

Strengths and weaknesses

This indicator is simple to calculate. Since both HIV and HBV treatment are given for life, the indicator is a measure of coverage, similar to HIV treatment.